Close Menu

NEW YORK – Adaptive Biotechnologies announced that its ClonoSeq assay is now available in all 50 states, following approval from the New York State Department of Health clinical laboratory evaluation program (CLEP), the firm said in a statement.

The assay received approval from NY State for detection and monitoring of minimal residual disease in patients with B cell blood cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.